orphan disease


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.

or·phan dis·ease

a disease for which no treatment has been developed because of its rarity (affecting no more than 200,000 persons in the U.S.).
See also: orphan products.

orphan disease

n.
A disease that is relatively rare, for which the development of drugs is considered to be commercially nonviable.

orphan disease

[ôr′fən]
any rare health disorder for which no treatment has been developed. See also orphan drug.
Any disorder affecting less than 200,000 people in the US (less than one per 1,000 people)—regarded by the pharmaceutical industry as too rare for developing commercially viable products

orphan disease

Medtalk A disorder affecting < 200,000 people–US–ie, < 1/1000 people. See NICODARD, NORD.

or·phan dis·ease

(ōr'făn di-zēz')
A disease for which no treatment has been developed because of the disorder's rarity.
See also: orphan products
References in periodicals archive ?
One of the main problems is, because of the small number of people with a particular orphan disease, running meaningful clinical trials is very difficult.
Daiichi Sankyo and Orphan Disease Treatment Institute will jointly conduct clinical and non-clinical studies with the cooperation and support of these two professors with the aim of achieving POC.
Charlie is an expert in LSDs with over 10 years' drug development experience in the rare and orphan disease space.
The 1985 amendments to the Act also established a National Commission on Orphan Diseases (NCOD) to evaluate government research activities on rare diseases.
PharmGPS(TM) Orphan Disease Suite BioXcel's proprietary Orphan Disease Suite encompasses more than 9,000 rare & ultra-rare diseases, 4,000 -5,000 associated genes, 1,500 disease pathways, and distinct target-indication tiles for antibody, protein, RNA, small molecule and gene therapy modalities.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today the opening of the office of the Orphan Disease Treatment Institute Co.
GBI Research, the leading business intelligence provider, has released its latest research, Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity, which provides insights into the global orphan diseases in genetic disorders therapeutics market, including market forecasts until 2018.
BRANFORD, Connecticut, June 11, 2014 /PRNewswire/ -- BioXcel Corporation, announced today its first-in-class cloud based Pharma big-data analytics platform, PharmGPS(TM) now has a dedicated Orphan Disease suite to aid in the discovery, development, licensing and commercialization of drugs for the approximately 7,000 Rare and Ultra Rare Diseases.
The new report* shows that the relatively unsatisfied market for orphan disease drugs could prove to be a big hit for pharmaceutical companies able to improve upon the limited options currently available to patients.
A popular section with readers; chapter 3 covers the average financial deal terms for deals signed in the orphan disease field with a stage of development announced.
uniQure has developed Glybera as a therapy for patients with the genetic disorder lipoprotein lipase deficiency, an orphan disease.
GBI Research, the leading business intelligence provider, has released its latest research Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules, which provides insights into the Oncology orphan disease therapeutics market until 2018.